Ana-Luisa Stefanski

Ana-Luisa Stefanski

Auto-generated profile, based on publicly available information

Ana-Luisa Stefanski

Department of Rheumatology and Clinical Immunology, Charité Universitätsmedizin Berlin, Berlin, Germany

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 June 2021 in Science Immunology
Verified
Journal Article
Open access
PDF file
HRHector Rincon-Arevalo
Hector Rincon-Arevalo
MCMira Choi
Mira Choi
ASAna-Luisa Stefanski
Ana-Luisa Stefanski
FHFabian Halleck
Fabian Halleck
UWUlrike Weber
Ulrike Weber
TDThomas Dörner
Thomas Dörner
Patients with kidney failure are at increased risk of SARS-CoV-2 infection, making effective vaccinations a critical need. It is not known how well mRNA vaccines induce B and plasma cell responses in dialysis patients (DPs) or kidney transplant recipients (KTRs) compared with healthy controls (HCs). We studied humoral and B cell responses of 35 HCs, 44 DPs, and 40 KTRs. Markedly impaired anti-BNT162b2 responses were identified among KTRs and DPs compared with HCs. In DPs, the response was delayed (3 to 4 weeks after boost) and reduced with anti-S1 IgG and IgA positivity in 70.5 and 68.2%, respectively. In contrast, KTRs did not develop IgG responses except for one patient who had a previous unrecognized infection and developed anti-S1 IgG. Most antigen-specific B cells (RBD+) were identified in the plasmablast or post-switch memory B cell compartments in HCs, whereas RBD+ B cells were enriched among pre-switch and naïve B cells from DPs and KTRs. The frequency and absolute number of antigen-specific circulating plasmablasts in the cohort correlated with the Ig response, a characteristic not reported for other vaccinations. In conclusion, these data indicated that immunosuppression resulted in impaired protective immunity after mRNA vaccination, including Ig induction with corresponding generation of plasmablasts and memory B cells. Thus, there is an urgent need to improve vaccination protocols in patients after kidney transplantation or on chronic dialysis.

19 May 2017 in Deutsches Ärzteblatt international
Verified
Journal Article
Closed access
ASAna-Luisa Stefanski
Ana-Luisa Stefanski
CTChristian Tomiak
Christian Tomiak
UPUwe Pleyer
Uwe Pleyer
TDThomas Dietrich
Thomas Dietrich
GBGerd Rüdiger Burmester
Gerd Rüdiger Burmester
TDThomas Dörner
Thomas Dörner
Sj?gren?s syndrome is a chronic inflammatory autoimmune disease of unknown origin, attacking in particular the tear and salivary glands. Sicca symptoms are the hallmarks of the disease which may also present with various organ manifestations. Due to...

9 May 2022 in JCI Insight
Verified
Journal Article
Open access
PDF file
ESEva Vanessa Schrezenmeier
Eva Vanessa Schrezenmeier
HRHector Rincon-Arevalo
Hector Rincon-Arevalo
AJAnnika Jens
Annika Jens
ASAna-Luisa Stefanski
Ana-Luisa Stefanski
CHCharlotte Hammett
Charlotte Hammett
KBKlemens Budde
Klemens Budde
Transplant recipients exhibit an impaired protective immunity after SARS-CoV-2 vaccination, potentially caused by mycophenolate (MPA) immunosuppression. Recent data from patients with autoimmune disorders suggest that temporary MPA hold might greatly improve booster vaccination outcomes. We applied a fourth dose of SARS-CoV-2 vaccine to 29 kidney transplant recipients during a temporary (5 weeks) MPA/azathioprine hold, who had not mounted a humoral immune response to previous vaccinations. Seroconversion until day 32 after vaccination was observed in 76% of patients, associated with acquisition of virus-neutralizing capacity. Interestingly, 21/25 (84%) calcineurin inhibitor–treated patients responded, but only 1/4 belatacept-treated patients responded. In line with humoral responses, counts and relative frequencies of spike receptor binding domain–specific (RBD-specific) B cells were markedly increased on day 7 after vaccination, with an increase in RBD-specific CD27 ++ CD38 + plasmablasts. Whereas overall proportions of spike-reactive CD4 + T cells remained unaltered after the fourth dose, frequencies were positively correlated with specific IgG levels. Importantly, antigen-specific proliferating Ki67 + and in vivo–activated programmed cell death 1–positive T cells significantly increased after revaccination during MPA hold, whereas cytokine production and memory differentiation remained unaffected. In summary, antimetabolite hold augmented all arms of immunity during booster vaccination. These data suggest further studies of antimetabolite hold in kidney transplant recipients.

17 April 2022 in Arthritis & Rheumatology
Verified
Journal Article
Open access
PDF file
ASAna‐Luisa Stefanski
Ana‐Luisa Stefanski
HRHector Rincon‐Arevalo
Hector Rincon‐Arevalo
ESEva Vanessa Schrezenmeier
Eva Vanessa Schrezenmeier
KKKirsten Karberg
Kirsten Karberg
FSFranziska Szelinski
Franziska Szelinski
TDThomas Dörner
Thomas Dörner
Objective: Patients with autoimmune inflammatory rheumatic diseases receiving rituximab (RTX) therapy are at higher risk of poor COVID‐19 outcomes and show substantially impaired humoral immune response to anti–SARS–CoV‐2 vaccine. However, the complex relationship between antigen‐specific B cells and T cells and the level of B cell repopulation necessary to achieve anti‐vaccine responses remain largely unknown.Methods: Antibody responses to SARS–CoV‐2 vaccines and induction of antigen‐specific B and CD4/CD8 T cell subsets were studied in 19 patients with rheumatoid arthritis (RA) or antineutrophil cytoplasmic antibody–associated vasculitis receiving RTX, 12 patients with RA receiving other therapies, and 30 healthy controls after SARS–CoV‐2 vaccination with either messenger RNA or vector‐based vaccines.Results: A minimum of 10 B cells per microliter (0.4% of lymphocytes) in the peripheral circulation appeared to be required for RTX‐treated patients to mount seroconversion to anti‐S1 IgG upon SARS–CoV‐2 vaccination. RTX‐treated patients who lacked IgG seroconversion showed reduced receptor‐binding domain–positive B cells (P = 0.0005), a lower frequency of Tfh‐like cells (P = 0.0481), as well as fewer activated CD4 (P = 0.0036) and CD8 T cells (P = 0.0308) compared to RTX‐treated patients who achieved IgG seroconversion. Functionally relevant B cell depletion resulted in impaired interferon‐γ secretion by spike‐specific CD4 T cells (P = 0.0112, r = 0.5342). In contrast, antigen‐specific CD8 T cells were reduced in both RA patients and RTX‐treated patients, independently of IgG formation.Conclusion: In RTX‐treated patients, a minimum of 10 B cells per microliter in the peripheral circulation is a candidate biomarker for a high likelihood of an appropriate cellular and humoral response after SARS–CoV‐2 vaccination. Mechanistically, the data emphasize the crucial role of costimulatory B cell functions for the proper induction of CD4 responses propagating vaccine‐specific B cell and plasma cell differentiation.

24 September 2019 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
SWSarah Y. Weißenberg
Sarah Y. Weißenberg
FSFranziska Szelinski
Franziska Szelinski
ESEva Schrezenmeier
Eva Schrezenmeier
ASAna-Luisa Stefanski
Ana-Luisa Stefanski
AWAnnika Wiedemann
Annika Wiedemann
TDThomas Dörner
Thomas Dörner
Autoimmune diseases (AID) such as systemic lupus erythematosus (SLE), primary Sjögren's syndrome (pSS), and rheumatoid arthritis (RA) are chronic inflammatory diseases in which abnormalities of B cell function play a central role. Although it is widely accepted that autoimmune B cells are hyperactive in vivo, a full understanding of their functional status in AID has not been delineated. Here, we present a detailed analysis of the functional capabilities of AID B cells and dissect the mechanisms underlying altered B cell function. Upon BCR activation, decreased spleen tyrosine kinase (Syk) and Bruton's tyrosine kinase (Btk) phosphorylation was noted in AID memory B cells combined with constitutive co-localization of CD22 and protein tyrosine phosphatase (PTP) non-receptor type 6 (SHP-1) along with hyporesponsiveness to TLR9 signaling, a Syk-dependent response. Similar BCR hyporesponsiveness was also noted specifically in SLE CD27− B cells together with increased PTP activities and increased transcripts for PTPN2, PTPN11, PTPN22, PTPRC, and PTPRO in SLE B cells. Additional studies revealed that repetitive BCR stimulation of normal B cells can induce BCR hyporesponsiveness and that tissue-resident memory B cells from AID patients also exhibited decreased responsiveness immediately ex vivo, suggesting that the hyporesponsive status can be acquired by repeated exposure to autoantigen(s) in vivo. Functional studies to overcome B cell hyporesponsiveness revealed that CD40 co-stimulation increased BCR signaling, induced proliferation, and downregulated PTP expression (PTPN2, PTPN22, and receptor-type PTPs). The data support the conclusion that hyporesponsiveness of AID and especially SLE B cells results from chronic in vivo stimulation through the BCR without T cell help mediated by CD40–CD154 interaction and is manifested by decreased phosphorylation of BCR-related proximal signaling molecules and increased PTPs. The hyporesponsiveness of AID B cells is similar to a form of functional anergy.

2 August 2022 in Arthritis & Rheumatology
Verified
Journal Article
Open access
FSFranziska Szelinski
Franziska Szelinski
ASAna Luisa Stefanski
Ana Luisa Stefanski
ESEva Vanessa Schrezenmeier
Eva Vanessa Schrezenmeier
HRHector Rincon‐Arevalo
Hector Rincon‐Arevalo
AWAnnika Wiedemann
Annika Wiedemann
TDThomas Dörner
Thomas Dörner
Objective: Altered composition of the B cell compartment in the pathogenesis of systemic lupus erythematosus (SLE) is characterized by expanded plasmablast and IgD–CD27– double‐negative B cell populations. Previous studies showed that double‐negative B cells represent a heterogeneous subset, and further characterization is needed.Methods: We analyzed 2 independent cohorts of healthy donors and SLE patients, using a combined approach of flow cytometry (for 16 healthy donors and 28 SLE patients) and mass cytometry (for 18 healthy donors and 24 SLE patients) and targeted RNA‐Seq analysis. To compare B cell subset formation during the acute immune response versus that during autoimmune disease, we investigated healthy donors at various time points after receipt of the BNT162b2 messenger RNA COVID‐19 vaccine and patients with acute SARS–CoV‐2 infection, using flow cytometry.Results: We found that IgD–CD27+ switched and atypical IgD–CD27– memory B cells, the levels of which were increased in SLE patients, represented heterogeneous populations composed of 3 different subsets each. CXCR5+CD19intermediate, CXCR5–CD19high, and CXCR5–CD19low populations were found in the switched memory and double‐negative compartments, suggesting the relatedness of IgD–CD27+ and IgD–CD27– B cells. We characterized a hitherto unknown and antigen‐experienced CXCR5–CD19low subset that was enhanced in SLE patients, had a plasmablast phenotype with diminished B cell receptor responsiveness, and expressed CD38, CD95, CD71, PRDM1, XBP1, and IRF4. Levels of CXCR5–CD19low subsets were increased and correlated with plasmablast frequencies in SLE patients and in healthy donors who received BNT162b2, suggesting their interrelationship and contribution to plasmacytosis. The detection of CXCR5–CD19low B cells among both CD27+ and CD27– populations calls into question the role of CD27 as a reliable marker of B cell differentiation.Conclusion: Our data suggest that CXCR5–CD19low B cells are precursors of plasmablasts. Thus, cotargeting this subset may have therapeutic value in SLE.